Cartesian Therapeutics (RNAC) Cash from Operations (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Cash from Operations of 22135000.0 for Q1 2026, up 4.21% year-over-year from 21240628.71 in Q1 2025, and down 24.97% quarter-over-quarter from 17712000.0 in Q4 2025.
Powered by 
Analysis
Cartesian Therapeutics (RNAC) Cash from Operations (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Cash from Operations for 12 consecutive years, with 22135000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 4.21% year-over-year to 22135000.0; the TTM figure through Mar 2026 stood at 72968000.0 (down 136.41% YoY), while the FY2025 annual figure was 73941000.0, down 212.33% from the prior year.
- Cash from Operations slipped to 22135000.0 in Q1 2026 per RNAC's latest filing, from 17712000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 13691000.0 in Q3 2024 and bottomed at 23286000.0 in Q4 2023.
- Historically, Cash from Operations has averaged 11914235.29 across 5 years, with a median of 12271000.0 in 2022.
- Annual changes were most pronounced in 2023 — Cash from Operations slumped 311.69% — and 2024, when it jumped 248.57%.
- Cartesian Therapeutics' Cash from Operations stood at 11849000.0 in 2022, then sank by 96.52% to 23286000.0 in 2023, then soared by 69.93% to 7002000.0 in 2024, then slumped by 152.96% to 17712000.0 in 2025, then fell by 24.97% to 22135000.0 in 2026.
- Business Quant data shows RNAC's Cash from Operations at 22135000.0 in Q1 2026, 17712000.0 in Q4 2025, and 15600000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Cartesian Therapeutics | 271.98 Mn | 271.98 Mn | - | -21.08 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -21.08 Mn |
| Mar 31, 2026 | -22.14 Mn |
| Dec 31, 2025 | -17.71 Mn |
| Sep 30, 2025 | -15.60 Mn |
| Jun 30, 2025 | -17.52 Mn |
| Mar 31, 2025 | -23.11 Mn |
| Dec 31, 2024 | -7.00 Mn |
| Sep 30, 2024 | 13.69 Mn |
| Jun 30, 2024 | -14.45 Mn |
| Mar 31, 2024 | -15.92 Mn |
| Dec 31, 2023 | -23.29 Mn |
| Sep 30, 2023 | -9.22 Mn |
| Jun 30, 2023 | -9.90 Mn |
| Mar 31, 2023 | -8.77 Mn |
| Dec 31, 2022 | -11.85 Mn |
| Sep 30, 2022 | 4.35 Mn |
| Jun 30, 2022 | -12.27 Mn |
| Mar 31, 2022 | -11.86 Mn |
| Dec 31, 2021 | -31.46 Mn |
| Sep 30, 2021 | -10.75 Mn |